Boyd Mudenda

750 total citations
20 papers, 435 citations indexed

About

Boyd Mudenda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Boyd Mudenda has authored 20 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Boyd Mudenda's work include Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (4 papers) and Diabetes Management and Education (3 papers). Boyd Mudenda is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (4 papers) and Diabetes Management and Education (3 papers). Boyd Mudenda collaborates with scholars based in United States, Zambia and United Kingdom. Boyd Mudenda's co-authors include Lindsay B. Robertson, Sam Leinster, Charles Michelo, Aditya Bardia, David M. Goldenberg, William A. Wegener, Pius Maliakal, Michael J. Guarino, Robert M. Sharkey and Leora Horn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Boyd Mudenda

20 papers receiving 424 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Boyd Mudenda United States 10 270 98 89 86 53 20 435
Kazuhiko Nakagami Japan 12 222 0.8× 85 0.9× 55 0.6× 130 1.5× 84 1.6× 28 511
Aarti Bhatia United States 12 282 1.0× 136 1.4× 26 0.3× 96 1.1× 58 1.1× 33 580
Joana Oliveira Portugal 13 185 0.7× 178 1.8× 15 0.2× 243 2.8× 45 0.8× 29 510
Gabriele Antonarelli Italy 12 258 1.0× 86 0.9× 55 0.6× 116 1.3× 65 1.2× 32 414
Matthew E. Witek United States 14 214 0.8× 111 1.1× 68 0.8× 146 1.7× 52 1.0× 50 578
Terry Evans United States 11 302 1.1× 65 0.7× 73 0.8× 171 2.0× 41 0.8× 24 420
Louise De Brot Brazil 17 174 0.6× 138 1.4× 29 0.3× 87 1.0× 68 1.3× 52 585
Neysa Garner United States 2 392 1.5× 103 1.1× 51 0.6× 102 1.2× 18 0.3× 2 529
Alejandro Andicoechea Spain 15 232 0.9× 145 1.5× 39 0.4× 58 0.7× 211 4.0× 26 492
Richard E. Hunter United States 14 105 0.4× 70 0.7× 50 0.6× 60 0.7× 33 0.6× 26 693

Countries citing papers authored by Boyd Mudenda

Since Specialization
Citations

This map shows the geographic impact of Boyd Mudenda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boyd Mudenda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boyd Mudenda more than expected).

Fields of papers citing papers by Boyd Mudenda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boyd Mudenda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boyd Mudenda. The network helps show where Boyd Mudenda may publish in the future.

Co-authorship network of co-authors of Boyd Mudenda

This figure shows the co-authorship network connecting the top 25 collaborators of Boyd Mudenda. A scholar is included among the top collaborators of Boyd Mudenda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boyd Mudenda. Boyd Mudenda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ailawadhi, Sikander, Asher Chanan‐Khan, Zi Chen, et al.. (2021). First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).. Journal of Clinical Oncology. 39(15_suppl). 7502–7502. 16 indexed citations
2.
Pemmaraju, Naveen, Boyd Mudenda, Cunlin Wang, et al.. (2020). Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy. Blood. 136(Supplement 1). 15–16. 4 indexed citations
3.
Mudenda, Boyd, et al.. (2018). DETERMINATION OF OXYTETRACYCLINE RESIDUE LEVELS IN EDIBLE TISSUES OF SLAUGHTERED CATTLE. SHILAP Revista de lepidopterología. 4 indexed citations
4.
Gounder, Mrinal M., Neeta Somaiah, Steven Attia, et al.. (2018). Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.. Journal of Clinical Oncology. 36(15_suppl). 11512–11512. 18 indexed citations
5.
Heist, Rebecca S., Michael J. Guarino, Gregory A. Masters, et al.. (2017). Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. Journal of Clinical Oncology. 35(24). 2790–2797. 139 indexed citations
6.
Faltas, Bishoy M., Elaine T. Lam, Philip J. Saylor, et al.. (2017). Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results. Annals of Oncology. 28. v301–v302. 15 indexed citations
7.
Mudenda, Boyd, et al.. (2017). Insights and efforts to control rabies in Zambia: Evaluation of determinants and barriers to dog vaccination in Nyimba district. PLoS neglected tropical diseases. 11(10). e0005946–e0005946. 12 indexed citations
8.
Tagawa, Scott T., Allyson J. Ocean, Elaine T. Lam, et al.. (2017). Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).. Journal of Clinical Oncology. 35(6_suppl). 327–327. 5 indexed citations
9.
Chilengi, Roma, et al.. (2017). Marketing of breast-milk substitutes in Zambia: evaluation of compliance to the international regulatory code. Journal of Public Health. 40(1). e1–e7. 8 indexed citations
10.
Michelo, Charles, et al.. (2016). Relationship between glycated haemoglobin and fasting plasma glucose among diabetic out-patients at the University Teaching Hospital, Lusaka, Zambia. Tanzania journal of health research. 18(3). 4 indexed citations
11.
Michelo, Charles, et al.. (2015). Glycaemic Control and Associated Self-Management Behaviours in Diabetic Outpatients: A Hospital Based Observation Study in Lusaka, Zambia. Journal of Diabetes Research. 2016. 1–9. 35 indexed citations
12.
Mudenda, Boyd, et al.. (2014). Glycaemic control in diabetic patients in Zambia. Pan African Medical Journal. 19. 354–354. 14 indexed citations
13.
Horak, Christine E., Lajos Pusztai, Boyd Mudenda, et al.. (2010). Abstract PD07-02: βIII Tubulin Expression by Immunohistochemistry (IHC) and mRNA in a Randomized Phase 2 Neoadjuvant Breast Cancer (BC) Study of Ixabepilone (ixa) Compared to Paclitaxel (pac). Cancer Research. 70(24_Supplement). PD07–2. 1 indexed citations
14.
Saura, Cristina, L-M Tseng, Sherry Kit Wa Chan, et al.. (2010). Abstract PD07-01: Phase 2 Study of Ixabepilone Versus Paclitaxel as Neoadjuvant Therapy for Early Stage Breast Cancer with Comparative Biomarker Analysis. Cancer Research. 70(24_Supplement). PD07–1. 1 indexed citations
15.
Gianni, Lorenzo, Florence Dalenc, Milvia Zambetti, et al.. (2009). Clinical and Pharmacokinetic Study of Ixabepilone (IXA) Plus Epirubicin (EPI) as Therapy for Women with Advanced Breast Cancer (BC).. Cancer Research. 69(24_Supplement). 2097–2097. 1 indexed citations
16.
Rugo, H. S., Mario Campone, D. Amadori, et al.. (2009). Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1029–1029. 38 indexed citations
17.
Lewin, Anne, Mei-Li Wen, Rolf-Peter Ryseck, et al.. (2009). Antiangiogenic (AG) Synergy with Ixabepilone (IXA): Translation of Preclinical Studies to the Clinical Setting.. Cancer Research. 69(24_Supplement). 206–206. 5 indexed citations
18.
Zambetti, Milvia, Florence Dalenc, Silvia Govi, et al.. (2008). Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1058–1058. 5 indexed citations
19.
Mudenda, Boyd, et al.. (1994). The relationship between serum p53 autoantibodies and characteristics of human breast cancer. British Journal of Cancer. 69(6). 1115–1119. 81 indexed citations
20.
Mudenda, Boyd, et al.. (1994). Serum p53 auto-antibodies: Incidence in familial breast cancer. European Journal of Cancer. 30(5). 580–584. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuhiko Nakagami Breakdown of academic impact, for papers by Aarti Bhatia Breakdown of academic impact, for papers by Joana Oliveira Breakdown of academic impact, for papers by Gabriele Antonarelli Breakdown of academic impact, for papers by Matthew E. Witek Breakdown of academic impact, for papers by Terry Evans Breakdown of academic impact, for papers by Louise De Brot Breakdown of academic impact, for papers by Neysa Garner Breakdown of academic impact, for papers by Alejandro Andicoechea Breakdown of academic impact, for papers by Richard E. Hunter
Rankless by CCL
2026